We argue that there is not enough evidence to safely offer focal therapy to men with Gleason grade group 3-5 prostate cancer. Click to show full abstract
We argue that there is not enough evidence to safely offer focal therapy to men with Gleason grade group 3-5 prostate cancer.
               
Click one of the above tabs to view related content.